AU2007310416A1 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases - Google Patents

Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases Download PDF

Info

Publication number
AU2007310416A1
AU2007310416A1 AU2007310416A AU2007310416A AU2007310416A1 AU 2007310416 A1 AU2007310416 A1 AU 2007310416A1 AU 2007310416 A AU2007310416 A AU 2007310416A AU 2007310416 A AU2007310416 A AU 2007310416A AU 2007310416 A1 AU2007310416 A1 AU 2007310416A1
Authority
AU
Australia
Prior art keywords
thymosin alpha
treatment
disease
ibd
colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007310416A
Other languages
English (en)
Inventor
Francesco Bistoni
Enrico Garaci
Guido Rasi
Luigina Romani
Paola Sinibaldi Vallebona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2007310416A1 publication Critical patent/AU2007310416A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2007310416A 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases Abandoned AU2007310416A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000584A ITRM20060584A1 (it) 2006-10-27 2006-10-27 Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni
ITRM2006A000584 2006-10-27
PCT/IT2007/000677 WO2008050363A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
AU2007310416A1 true AU2007310416A1 (en) 2008-05-02

Family

ID=39322489

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007310416A Abandoned AU2007310416A1 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases

Country Status (13)

Country Link
US (1) US20100004174A1 (https=)
EP (1) EP2086569A2 (https=)
JP (1) JP2010507650A (https=)
KR (1) KR20090096688A (https=)
CN (1) CN101534853A (https=)
AU (1) AU2007310416A1 (https=)
BR (1) BRPI0718010A2 (https=)
CA (1) CA2666609A1 (https=)
EA (1) EA200900602A1 (https=)
IL (1) IL198291A0 (https=)
IT (1) ITRM20060584A1 (https=)
MX (1) MX2009004196A (https=)
WO (1) WO2008050363A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100248272A1 (en) * 2009-03-31 2010-09-30 Cornell University Method for identifying Smk box riboswitch modulating compounds
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW249754B (https=) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
CA2270223A1 (en) * 1996-10-28 1998-05-07 Carson B. Burgstiner (Deceased) Methods and compositions for dietary supplementation
CN1198950A (zh) * 1998-04-24 1998-11-18 崔泊 一种结肠炎新药的制备
CN1628796A (zh) * 2004-08-20 2005-06-22 康合堂 一种治疗溃疡性结肠炎的药物

Also Published As

Publication number Publication date
WO2008050363A2 (en) 2008-05-02
ITRM20060584A1 (it) 2008-04-28
KR20090096688A (ko) 2009-09-14
JP2010507650A (ja) 2010-03-11
WO2008050363A3 (en) 2008-06-26
WO2008050363A8 (en) 2009-06-04
CN101534853A (zh) 2009-09-16
EA200900602A1 (ru) 2009-10-30
BRPI0718010A2 (pt) 2013-11-19
CA2666609A1 (en) 2008-05-02
EP2086569A2 (en) 2009-08-12
MX2009004196A (es) 2009-06-30
IL198291A0 (en) 2011-08-01
US20100004174A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
Ridge et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone
CN111542335A (zh) 炎症性肠病的治疗药
KR20130036217A (ko) 라퀴니모드를 이용한 루푸스 관절염의 치료
US20150079083A1 (en) Alpha B-Crystallin as a Therapy for Ischemia or Inflammation
AU2023233094B2 (en) Anti-inflammatory agents
Kumar et al. Novel formulation approaches used for the management of osteoarthritis: a recent review
Jin et al. The protective effects of nesfatin‐1 in neurological dysfunction after spinal cord injury by inhibiting neuroinflammation
Karataş et al. Mango ginger (curcuma amada) inhibits collagen-induced arthritis by modulatinginflammatory cytokine levels in rats
US20100004174A1 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
CN115052613B (zh) 包含肽或肽混合物作为活性成分的组合物及其医疗用途
JP2009533421A (ja) 炎症性疾患を治療するためのアセチルコリンエステラーゼに対するアンチセンスオリゴヌクレオチド
CN116019813B (zh) Vesatolimod在制备预防和/或治疗中枢神经系统疾病的药物中的应用
Pan et al. Angelicin alleviates sepsis-associated encephalopathy via inhibition of IKK2 and the NF-κB pathway
JP5536037B2 (ja) 自己免疫疾患の治療における、ｐａｔノナペプチドの使用
KR20080048542A (ko) 인간 유두종 바이러스에 저항하는 약제 제조를 위한노카르디아 루브라 세포벽 골격의 용도
CN108210886A (zh) Metrnl在防治溃疡性结肠炎中的应用
EA032432B1 (ru) Специфический аналог трифторэтилхинолина для применения при лечении синдрома шегрена
CN120983423B (zh) 狭叶依瓦菊素在制备预防和/或治疗神经炎症的药物中的用途
JP4333901B2 (ja) リウマチ関節炎治療用プロディギオシン組成物
HK1137651A (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
Yoo et al. 10-or 30-minute treadmill exercise rescues motor behaviors through inhibiting apoptosis in a rat MCAo model
WO2021240204A1 (en) Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy
Spyridon A Systematic Review of efficacy and safety of Biologic Agents as treatment options for Myositis
CN121891503A (zh) 一种新型肽upcp在制备治疗和/或预防银屑病药物中的应用
EP4429647A1 (en) Compositions for the management of demyelinating disorders

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period